Evidence map›Paper›PMID 27653685›Full record

ArticleCell reports2016

Multivalent Chromatin Engagement and Inter-domain Crosstalk Regulate MORC3 ATPase.

Forest H Andrews, Qiong Tong, Kelly D Sullivan, Evan M Cornett, Yi Zhang, Muzaffar Ali, JaeWoo Ahn, Ahway Pandey, Angela H Guo, Brian D Strahl and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. TheNeural regeneration research · 2024
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. MORC3 Is a Target of the Influenza A Viral Protein NS1.Structure (London, England : 1993) · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Forest H AndrewsDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Qiong TongDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Kelly D SullivanDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045, USA; Linda Crnic Institute for Down Syndrome, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Evan M CornettCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, MI 49503, USA.
Yi ZhangDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Muzaffar AliDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
JaeWoo AhnDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Ahway PandeyDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045, USA; Linda Crnic Institute for Down Syndrome, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Angela H GuoDepartment of Biochemistry and Biophysics, The University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.
Brian D StrahlDepartment of Biochemistry and Biophysics, The University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.
James C CostelloDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Joaquin M EspinosaDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045, USA; Linda Crnic Institute for Down Syndrome, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Scott B RothbartCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, MI 49503, USA.
Tatiana G KutateladzeDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045, USA. Electronic address: tatiana.kutateladze@ucdenver.edu.
University of Colorado Denver · USUniversity of North Carolina at Chapel Hill · USVan Andel Institute · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
BEHAVIORAL PHARMACOGENETICS OF DRUG AND ALCOHOL ABUSET32AA007464 · NIAAA · UNIVERSITY OF COLORADO DENVER · PI HOFFMAN, PAULA · 1987 to 2017
$4.8M
Stress- and Promoter-Specific Mechanisms of Transcritpional Activation by p53R01CA117907 · NCI · UNIVERSITY OF COLORADO DENVER · PI ESPINOSA, JOAQUIN M. · 2006 to 2022
$4.4M
Researcher Resilience through Multidimensional MentoringDP4GM096850 · NIGMS · UNIVERSITY OF ROCHESTER · PI LEWIS, VIVIAN · 2010 to 2010
$2.0M
Epigenetic regulation by PHF1R01GM106416 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2015 to 2018
$1.5M
Molecular mechanism of chromatin targeting by BRPF1R01GM100907 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2015 to 2018
$1.4M
Factors that regulate chromatin organization and gene transcriptionR01GM110058 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI STRAHL, BRIAN D · 2014 to 2017
$1.2M
Mechanisms Regulating DNA Methylation Maintenance in ChromatinR00CA181343 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI ROTHBART, SCOTT · 2015 to 2017
$746k
Mechanisms Regulating DNA Methylation Maintenance in ChromatinK99CA181343 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROTHBART, SCOTT · 2014 to 2015
$211k
NCATS NIH HHS UL1 TR001082NCI NIH HHS K99 CA181343NCI NIH HHS P30 CA046934NCI NIH HHS R00 CA181343NCI NIH HHS R01 CA117907NIAAA NIH HHS T32 AA007464NIGMS NIH HHS R01 GM100907NIGMS NIH HHS R01 GM106416NIGMS NIH HHS R01 GM110058
6 · The paper itself

Abstract

MORC3 is linked to inflammatory myopathies and cancer; however, the precise role of MORC3 in normal cell physiology and disease remains poorly understood. Here, we present detailed genetic, biochemical, and structural analyses of MORC3. We demonstrate that MORC3 is significantly upregulated in Down syndrome and that genetic abnormalities in MORC3 are associated with cancer. The CW domain of MORC3 binds to the methylated histone H3K4 tail, and this interaction is essential for recruitment of MORC3 to chromatin and accumulation in nuclear bodies. We show that MORC3 possesses intrinsic ATPase activity that requires DNA, but it is negatively regulated by the CW domain, which interacts with the ATPase domain. Natively linked CW impedes binding of the ATPase domain to DNA, resulting in a decrease in the DNA-stimulated enzymatic activity. Collectively, our studies provide a molecular framework detailing MORC3 functions and suggest that its modulation may contribute to human disease.

Indexed as

Adenosine TriphosphatasesCells, CulturedChromatinDNA-Binding ProteinsDown SyndromeHistidine KinaseHumansNeoplasmsProtein ConformationProtein DomainsAdenosine TriphosphatasesChromatinDNA-Binding ProteinsHistidine KinaseMORC3 protein, human

Identifiers

PMID27653685
PMCPMC5074691
OpenAlexW2522920940

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.